Finally, we demonstrated that quantification of LPL and ADAM29 gene expression ratio is a strong prognostic indicator in CLL, providing better prognostic assessment than serologic markers in advanced stages of the disease [26]. The gene discussed is LPL; the disease is B-cell chronic lymphocytic leukemia.